ERLEADA® (apalutamide) demonstrates statistically significant …
WEB2 days ago · Johnson Johnson (NYSE: JNJ) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA ® (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon ...
Johnson & Johnson's Erleada Shows Improved Overall Survival In …
WEB2 days ago · Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc’s (NYSE:PFE) Xtandi (enzalutamide). The data showed that ...
J&J’s Erleada provides survival edge over Astellas’ Xtandi
WEB1 day ago · The study looked at treatment outcomes for more than 3,700 patients and found that Erleada reduced the risk of death by 23% over Xtandi after 24 months, J&J said in a Tuesday release. The ...
Apalutamide associated with improved survival vs enzalutamide in …
WEB2 days ago · Apalutamide (Erleada) was found to provide a significant improvement in overall survival (OS) at 24 months compared with enzalutamide (Xtandi) in the treatment of androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer (mCSPC), according to data from a head-to-head retrospective analysis presented at the 6th European Congress of Oncology ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBSAN ANTONIO, May 3, 2024 – Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA ® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP).
JNJ's Erleada Shows Statistically Significant Overall Survival In ...
WEB2 days ago · Johnson & Johnson (), Wednesday announced results from a head-to-head study, demonstrating statistically significant overall survival benefit in patients on Erleada at 24 months compared to Enzalutamide in patients with metastatic castration-sensitive prostate cancer.The analysis found that patients who initiated Erleada as their first androgen receptor pathway inhibitor had a statistically ...
Phase 2 data for ERLEADA® (apalutamide) plus androgen …
WEBMay 3, 2024 · Johnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in...
Janssen Announces Treatment with ERLEADA - Johnson & Johnson
WEBRARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, …
ERLEADA® (apalutamide) demonstrates statistically significant …
WEB2 days ago · The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA ® cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 ...
ERLEADA® (apalutamide) demonstrates statistically significant …
WEB2 days ago · The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA ® cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent). 1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA ® plus androgen deprivation therapy (ADT) compared to ADT ...